Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 9/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4604077 | 0.91 | CYP1A2 (0.40) | GABRA5CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4607421 | 0.91 | CYP1A2 (0.49) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL4981274 | 0.90 | NR1H4 (0.40) | GABRA5 | |
| SCHEMBL4980783 | 0.87 | GABRA5 (0.56) | GABRA5ALDH1A1LMNA | |
| SCHEMBL14188863 | 0.86 | TSHR (0.52) | GABRA5MAPTRECQLHTTSMN1; SMN2 | |
| SCHEMBL4605381 | 0.85 | GPBAR1 (0.46) | GABRA5CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL14188872 | 0.85 | SMN1; SMN2 (0.59) | GABRA5HTTSMN1; SMN2GAATSHR | |
| SCHEMBL4980741 | 0.85 | GABRA5 (0.53) | GABRA5CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4605621 | 0.85 | GABRA5 (0.50) | GABRA5GPBAR1MAPTRECQLSMN1; SMN2 | |
| SCHEMBL4981910 | 0.84 | CYP1A2 (0.44) | GABRA5CYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7378435-B2 | Aryl-isoxazole-4-carbonyl-indole-carboxylic acid amide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-05-27 | — | — | US | disclosed |
| US-7378435-B2 | Aryl-isoxazole-4-carbonyl-indole-carboxylic acid amide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-05-27 | — | — | US | disclosed |
| US-7378435-B2 | Aryl-isoxazole-4-carbonyl-indole-carboxylic acid amide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-05-27 | — | — | US | disclosed |
| US-20070082936-A1 | Aryl-isoxazole-4-carbonyl-indole-carboxylic acid amide derivatives | HOFFMANN-LA ROCHE INC. | 2007-04-12 | — | — | US | disclosed |
| US-20070082936-A1 | Aryl-isoxazole-4-carbonyl-indole-carboxylic acid amide derivatives | HOFFMANN-LA ROCHE INC. | 2007-04-12 | — | — | US | disclosed |
| US-20070082936-A1 | Aryl-isoxazole-4-carbonyl-indole-carboxylic acid amide derivatives | HOFFMANN-LA ROCHE INC. | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082936-A1 | Aryl-isoxazole-4-carbonyl-indole-carboxylic acid amide derivatives | GABRA5, GABRA4, CHRNA5 | GABRA5 1/4885CYP1A2 313/4885CYP3A4 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.